Avior is a clinical stage, pharmaceutical company developing drugs for distressed neurological conditions. Using its disruptive drug delivery technology – Speedit™ Transmucosal Film Technology – we are positioned to develop products that bring unsurpassed value in efficacy and safety. Avior has an excellent management team, strong advisory board, supportive partners, dedicated scientists and knowledgeable clinicians that position us to be successful.
Our lead product – AV104 buccal film- focuses on the treatment for moderate to severe pruritus in patients suffering from liver disease.
Innovative Drug Delivery. Improved Therapeutics.
Niraj Vasisht is the CEO at Avior. He has 25+ years of experience in the pharmaceutical industry from drug development to product launch. Prior to this, he was the Chief Technology Officer at Bio Delivery Sciences (Nasdaq: BDSI) where he co-led the development and approval of three commercial products – BELBUCA®, BUNAVAIL®, and ONSOLIS®. Along with the management team, Dr. Vasisht participated in raising approximately $160M in capital through equity, partnerships and debt financing. Prior to BDSI, Dr. Vasisht served as Director at Southwest Research Institute where he ran a small business unit and led a team of prolific researchers in product conceptualization, product development, engineering scale-up and commercial manufacturing across pharmaceutical, consumer health, and nutraceutical industry. There, he contributed to the early stage development of nutraceuticals (meg-3®), OTC (Citracal-D®), and a pharmaceutical Rx product (Probuphine®). He is a key-opinion-leader (KOL) in the field of delivery technologies. He is the inventor of 19 patents and many publications. He co-authored several book chapters and co-edited a reference book namely, “Microencapsulation for the Food Industry: A Practical Guide” (Elsevier). He sits on the Board of Defender Pharma and Mucodel Pharma. He received a Bachelor’s in Chemical Engineering from the Indian Institute of Technology, and a Ph.D. in Chemical Engineering from Rensselaer Polytechnic Institute.
Advisor – Clinical and Regulatory Affairs
Andrew Finn serves as an Advisor and Emeritus Chief Medical Officer at Avior. He has over 35+ years of experience in product development including clinical research (US and international), preclinical research, data management, statistics, regulatory affairs (US and European) and pharmaceutical development. Dr. Finn was the founder and Chief Operating Officer of Arius Pharmaceutical which was successfully acquired by BioDelivery Sciences (BDSI: Nasdaq) , and which later went on the develop and commercialize – BELBUCA®, BUNAVAIL®, and ONSOLIS®. Prior to BDSI, he was the Executive VP of Product Development at Pozen, and VP of Clinical Research at Solvay, and Director of Clinical Development at Glaxo. Dr. Finn has a Bachelor’s in Pharmacy from University of North Carolina -Chapel Hill and a Doctorate in Pharmacy from University of Michigan.
Advisor – Preclinical Development
Dr. Christensen have over 20+ years of experience as a biotech executive managing pre-clinical discovery and pharmacology efforts across respiratory, inflammation, CNS, anti-infective, and oncology indications. He has been responsible for clinical trial design, biomarker development and toxicology study design. He is currently an Adjunct Associate Professor of Medicine (Hematology) at Duke University Medical Center and held senior positions at Oncotide, Cognosci, Affinergy Inc., Aryzun Pharmaceuticals, and KaroBio USA, formerly Novalon Pharmaceuticals. Dr. Christensen received his B.S. in Chemistry from Utah State University, and a Ph.D. in Organic Chemistry from the University of Utah. He was an NIH Postdoctoral Fellow at Texas A&M University. He has published many papers and is an inventor on numerous patents and patent applications in drug discovery.